{"id":"W4281683029","doi":"10.1200/jco.2022.40.16_suppl.7503","title":"First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Vinblastine; Internal medicine; Oncology; Bleomycin; Population; Progression-free survival; Chemotherapy regimen; Chemotherapy; Surgery; Lymphoma; Vincristine; Hodgkin lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002260815,0.000376192,0.001122165,0.0004608246,0.0001211658,0.0006459478,0.0004472819,0.0003492594,0.001573075],"category_scores_gemma":[0.001696624,0.0002087937,0.002101685,0.0006395927,0.0002163773,0.000523728,0.0003764826,0.0009121008,0.0001769107],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008363262,"about_ca_system_score_gemma":0.000671608,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001075705,"about_ca_topic_score_gemma":0.004583885,"domain_scores_codex":[0.9994597,0.0002267896,0.00005440116,0.00008842847,0.0001064092,0.00006426753],"domain_scores_gemma":[0.9988055,0.0003672921,0.0004460295,0.00008902624,0.00009730077,0.0001948691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3011368,0.002425341,0.1905854,0.005397704,0.02387038,0.0003042881,0.0002509328,0.003606479,0.007882693,0.0004707813,0.008257821,0.4558114],"study_design_scores_gemma":[0.1143376,0.09487263,0.7075741,0.001345291,0.04680882,0.001515851,0.0002057043,0.003960445,0.002645694,0.0009573516,0.0256658,0.0001107275],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9236732,0.06807423,0.0007491722,0.001104676,0.0001819112,0.0005491673,0.003328872,0.00005837629,0.00228042],"genre_scores_gemma":[0.9789987,0.01340981,0.001090856,0.001067442,0.0001921521,0.0002877014,0.004086447,0.00001553387,0.0008515284],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002260815,"threshold_uncertainty_score":0.01195651,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04392624238914087,"score_gpt":0.3851031776836114,"score_spread":0.3411769352944705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}